Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab-induced remission in CIDP (ReCIX)
2024-512506-25-00Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of rituximab in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Remission at 52 weeks after start of rituximab. Planned start Aug 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2024-512506-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512506-25-00.